NCT06887348 A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
| NCT ID | NCT06887348 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Replimune, Inc. |
| Condition | Melanoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-12-12 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2025-12-12 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose of an RPx product under the interventional parent study. Patients will be rolled over into this LTFU study after completion of the Replimune-sponsored parent study (ie, either completion of the LTFU in the parent study or withdrawal from the parent study). All patients in ongoing RPx studies will be asked to participate in this LTFU study so that the Sponsor can evaluate potential delayed risks.
Eligibility Criteria
Inclusion Criteria: Patients are eligible for inclusion in the study only if they meet all of the following criteria: 1. Patient has received at least 1 dose of an RPx product and has completed or discontinued participation in the parent study. 2. Patient or patient's legal guardian has provided signed informed consent (or assent) as , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria: Patients are excluded from the study if the following criterion applies: 1\. Cannot comply with the requirements of the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06887348 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Melanoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06887348 currently recruiting?
Yes, NCT06887348 is actively recruiting participants. Contact the research team at Clinicaltrials@replimune.com for enrollment information.
Where is the NCT06887348 trial being conducted?
This trial is being conducted at La Jolla, United States, Southport, Australia.
Who is sponsoring the NCT06887348 clinical trial?
NCT06887348 is sponsored by Replimune, Inc.. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.